ArticleThe Journal of infectious diseases2026
Antibiotic and Nonantibiotic Drugs Associated With Clostridioides difficile Infection Risk: a Pharmacopoeia-Wide Case-Cohort Study.
Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Burden and Mortality Outcomes ofJournal of clinical medicine · 2026Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClostridioides difficile infection (CDI) is principally precipitated by antibiotics, due to their disruption of gut commensal bacteria. The comparative role of nonantibiotic drugs is poorly characterized.
methodsWe examined the contribution of antibiotic and nonantibiotic drugs to CDI risk among residents age >65 years old and not hospitalized in the prior 30 days, between 2018 and 2023. The study used a case-cohort study design, with logistic regression analysis. The case definition consisted of first incident CDI, identified using comprehensive C. difficile testing, hospitalization, and treatment data. Outpatient oral drug exposures were measured in a 1-90-day window prior to case and control days. Adjusted regression models included covariates for age, sex, year and quarter, region, comorbid conditions, healthcare exposures, and drug exposures.
resultsAmong 16 196 CDI case patients and 549 831 controls, 335 drugs were included. After adjustment, the antibiotics amoxicillin-clavulanate (odds ratio [OR], 6.05 [95% confidence interval (CI), 5.69-6.43]), clindamycin (16.83 [15.53-18.24]), ciprofloxacin (3.83 [3.59-4.09]), and cephalexin (3.05 [2.86-3.25]), were the largest contributors to CDI risk. Nonantibiotic drugs pantoprazole (OR, 1.33 [95% CI, 1.27-1.39]) and ferrous fumarate (1.71 [1.61-1.82]) were the next largest. Metformin had a protective association (OR, 0.67 [95% CI, .63-.72]). In a meta-regression on a subset of 182 drugs, in vitro anticommensal activity was positively associated with CDI risk (P < .001).
conclusionsThis study provides insights into CDI etiology and avenues for stewardship and drug repurposing to combat CDI and antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.